{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T20:41:49Z","timestamp":1780519309101,"version":"3.54.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2020,9,24]],"date-time":"2020-09-24T00:00:00Z","timestamp":1600905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,9,24]],"date-time":"2020-09-24T00:00:00Z","timestamp":1600905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1208\/s12249-020-01795-w","type":"journal-article","created":{"date-parts":[[2020,9,24]],"date-time":"2020-09-24T22:02:58Z","timestamp":1600984978000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Quality by Design Adapted Chemically Engineered Lipid Architectonics for HIV Therapeutics and Intervention: Contriving of Formulation, Appraising the In vitro Parameters and In vivo Solubilization Potential"],"prefix":"10.1208","volume":"21","author":[{"given":"Bushra","family":"Nabi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saleha","family":"Rehman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumit","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjula","family":"Baboota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,24]]},"reference":[{"key":"1795_CR1","unstructured":"UNAIDS report 2019. https:\/\/www.unaids.org\/en\/resources\/fact-sheet Last accessed on 08 Feb 2020; 13:03 pm."},{"issue":"4","key":"1795_CR2","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1001\/jama.2014.8722","volume":"312","author":"FH G\u00fcnthard","year":"2014","unstructured":"G\u00fcnthard FH, Aberg JA, Eron JJ, Hoy JF, Telenti A, Benson CA, et al. Antiretroviral treatment of adult HIV infection 2014 recommendations of the International Antiviral Society\u2013USA Panel. JAMA. 2014;312(4):410\u201325.","journal-title":"JAMA."},{"key":"1795_CR3","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.coviro.2016.03.004","volume":"18","author":"T Cihlar","year":"2014","unstructured":"Cihlar T, Fordyce M. Current status and prospects of HIV treatment. Curr Opin Virol. 2014;18:50\u20136.","journal-title":"Curr Opin Virol"},{"key":"1795_CR4","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1208\/s12249-018-1284-9","volume":"20","author":"B Nabi","year":"2019","unstructured":"Nabi B, Rehman S, Baboota S, Ali J. Insights on oral drug delivery of lipid nanocarriers: a win-win solution for augmenting bioavailability of antiretroviral drugs. AAPS PharmSciTech. 2019;20:60.","journal-title":"AAPS PharmSciTech"},{"issue":"4","key":"1795_CR5","doi-asserted-by":"publisher","first-page":"182","DOI":"10.4103\/2230-973X.167661","volume":"5","author":"S Khan","year":"2015","unstructured":"Khan S, Baboota S, Ali J, Khan S, Narang RS, Narang JS. Nanostructured lipid carriers: an emerging platform for improving oral bioavailability of lipophilic drugs. Int J Pharm Investig. 2015;5(4):182\u201391.","journal-title":"Int J Pharm Investig"},{"key":"1795_CR6","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.jconrel.2017.08.033","volume":"264","author":"C Tapeinos","year":"2017","unstructured":"Tapeinos C, Battaglini M, Ciofani G. Advances in the design of solid lipid nanoparticles and nanostructured lipid carriers for targeting brain diseases. J Control Release. 2017;264:306\u201332.","journal-title":"J Control Release"},{"key":"1795_CR7","first-page":"1","volume":"54","author":"N Fatima","year":"2019","unstructured":"Fatima N, Rehman S, Nabi B, Baboota S, Ali J. Harnessing nanotechnology for enhanced topical delivery of clindamycin phosphate. J Drug Deliv Sci Technol. 2019;54:1\u201312.","journal-title":"J Drug Deliv Sci Technol."},{"key":"1795_CR8","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ifset.2013.03.002","volume":"19","author":"F Tamjidi","year":"2013","unstructured":"Tamjidi F, Shahedi M, Varshosaz J, Nasirpour A. Nanostructured lipid carriers (NLC): a potential delivery system for bioactive food molecules. Innov Food Sci Emerg Technol. 2013;19:29\u201343.","journal-title":"Innov Food Sci Emerg Technol"},{"issue":"3","key":"1795_CR9","doi-asserted-by":"publisher","first-page":"FSO135","DOI":"10.4155\/fsoa-2016-0030","volume":"2","author":"N Poonia","year":"2016","unstructured":"Poonia N, Kharb R, Lather V, Pandita D. Nanostructured lipid carriers: versatile oral delivery vehicle. Future Sci OA. 2016;2(3):FSO135.","journal-title":"Future Sci OA"},{"issue":"12","key":"1795_CR10","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1080\/17425247.2019.1684895","volume":"16","author":"S Rehman","year":"2019","unstructured":"Rehman S, Nabi B, Zafar A, Baboota S, Ali J. Intranasal delivery of mucoadhesive nanocarriers: a viable option for Parkinson\u2019s disease treatment? Expert Opin Drug Deliv. 2019;16(12):1355\u201366.","journal-title":"Expert Opin Drug Deliv."},{"key":"1795_CR11","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1007\/s11095-017-2136-0","volume":"34","author":"SMT Cavalcanti","year":"2017","unstructured":"Cavalcanti SMT, Nunes C, Lima SAC, Soares-Sobrinho JL, Reis S. Multiple lipid nanoparticles (MLN), a new generation of lipid nanoparticles for drug delivery systems: lamivudine-MLN experimental design. Pharm Res. 2017;34:1204\u201316.","journal-title":"Pharm Res"},{"key":"1795_CR12","doi-asserted-by":"crossref","unstructured":"Chakraborty T, Das MK, Dutta L, Mukherjee B, Das S, Sarma A. Successful delivery of zidovudine-loaded docosanol nanostructured lipid carriers (docosanol NLCs) into rat brain. In: Pathak Y, editors. Surface modification of nanoparticles for targeted drug delivery. 2019. p. 245\u2013276.","DOI":"10.1007\/978-3-030-06115-9_14"},{"issue":"2","key":"1795_CR13","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3390\/pharmaceutics11020097","volume":"11","author":"AA Khan","year":"2019","unstructured":"Khan AA, Mudassir J, Akhtar S, Murugaiyah V, Darwis Y. Freeze-dried lopinavir-loaded nanostructured lipid carriers for enhanced cellular uptake and bioavailability: statistical optimization, in vitro and in vivo evaluations. Pharmaceutics. 2019;11(2):97.","journal-title":"Pharmaceutics."},{"key":"1795_CR14","doi-asserted-by":"crossref","unstructured":"Alam T, Khan S, Gaba B, Haider MF, Baboota S, Ali J. Adaptation of quality by design-based development of isradipine nanostructured - lipid carrier and its evaluation for in vitro gut permeation and in vivo solubilization fate. J Pharm Sci. 2018;1\u201313.","DOI":"10.1016\/j.xphs.2018.07.021"},{"key":"1795_CR15","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.molliq.2018.01.141","volume":"255","author":"B Iqbal","year":"2017","unstructured":"Iqbal B, Ali J, Baboota S. Silymarin loaded nanostructured lipid carrier: from design and dermatokinetic study to mechanistic analysis of epidermal drug deposition enhancement. Molliq. 2017;255:513\u201329. https:\/\/doi.org\/10.1016\/j.molliq.2018.01.141.","journal-title":"Molliq."},{"issue":"9","key":"1795_CR16","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/j.ejmech.2007.01.024","volume":"42","author":"S Dubey","year":"2007","unstructured":"Dubey S, Satyanarayana YD, Lavania. Development of integrase inhibitors for treatment of AIDS: an overview. Eur J Med Chem. 2007;42(9):1159\u201368.","journal-title":"Eur J Med Chem"},{"issue":"4","key":"1795_CR17","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1097\/QAD.0000000000001349","volume":"31","author":"M Subhra","year":"2017","unstructured":"Subhra M, Prathipati PK, Guobin K, You Z, Zhe Y, Wenjin F, et al. Tenofovir alafenamide and elvitegravir loaded nanoparticles for long-acting prevention of HIV-1 vaginal transmission. AIDS. 2017;31(4):469\u201376.","journal-title":"AIDS."},{"key":"1795_CR18","first-page":"81","volume":"6","author":"KK Pandey","year":"2014","unstructured":"Pandey KK. Critical appraisal of elvitegravir in the treatment of HIV-1\/AIDS. HIV AIDS (Auckl). 2014;6:81\u201390.","journal-title":"HIV AIDS (Auckl)"},{"key":"1795_CR19","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.ejpb.2016.07.017","volume":"108","author":"S Khan","year":"2016","unstructured":"Khan S, Shaharyar M, Fazil M, Baboota S, Ali J. Tacrolimus-loaded nanostructured lipid carriers for oral delivery - optimization of production & characterization. Eur J Pharm Biopharm. 2016;108:277\u201388. https:\/\/doi.org\/10.1016\/j.ejpb.2016.07.017.","journal-title":"Eur J Pharm Biopharm"},{"key":"1795_CR20","doi-asserted-by":"publisher","first-page":"101545","DOI":"10.1016\/j.jddst.2020.101545","volume":"56","author":"VC Gurumukhi","year":"2020","unstructured":"Gurumukhi VC, Bari SB. Fabrication of efavirenz loaded nano-formulation using quality by design (QbD) based approach: exploring characterizations and in vivo safety. J Drug Deliv Sci Technol. 2020;56:101545. https:\/\/doi.org\/10.1016\/j.jddst.2020.101545.","journal-title":"J Drug Deliv Sci Technol"},{"issue":"7","key":"1795_CR21","doi-asserted-by":"publisher","first-page":"E599","DOI":"10.3390\/pharmaceutics12070599","volume":"12","author":"S Cunha","year":"2020","unstructured":"Cunha S, Costa CP, Loureiro JA, Alves J, Peixoto AF, Forbes B, et al. Double optimization of rivastigmine-loaded nanostructured lipid carriers (NLC) for nose-to-brain delivery using the quality by design (QbD) approach: formulation variables and instrumental parameters. Pharmaceutics. 2020;12(7):E599. https:\/\/doi.org\/10.3390\/pharmaceutics12070599.","journal-title":"Pharmaceutics."},{"key":"1795_CR22","doi-asserted-by":"publisher","unstructured":"Rangaraj N, Pailla SR, Shah S, Prajapati S, Sampathi S. QbD aided development of ibrutinib-loaded nanostructured lipid carriers aimed for lymphatic targeting: evaluation using chylomicron flow blocking approach [published online ahead of print, 2020 Jun 9]. Drug Deliv Transl Res. 2020. https:\/\/doi.org\/10.1007\/s13346-020-00803-7.","DOI":"10.1007\/s13346-020-00803-7"},{"key":"1795_CR23","first-page":"119","volume":"11","author":"Z Teng","year":"2019","unstructured":"Teng Z, Yu M, Ding Y, Zhang H, Shen Y, Jiang M, et al. Preparation and characterization of nimodipine loaded nanostructured lipid systems for enhanced solubility and bioavailability. Int J Nanomedicine. 2019;11:119\u201333.","journal-title":"Int J Nanomedicine"},{"issue":"2","key":"1795_CR24","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1517\/17425247.2014.945416","volume":"12","author":"TPJ Alam","year":"2015","unstructured":"Alam TPJ, Vohora D, Aqil M, Ali A, Sultana Y. Optimization of nanostructured lipid carriers of lamotrigine for brain delivery: in vitro characterization and in vivo efficacy in epilepsy. Expert Opin Drug Deliv. 2015;12(2):181\u201394.","journal-title":"Expert Opin Drug Deliv"},{"key":"1795_CR25","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.ijpharm.2013.03.034","volume":"454","author":"H Shete","year":"2013","unstructured":"Shete H, Patravale V. Long chain lipid based tamoxifen NLC. Part I: preformulation studies, formulation development and physicochemical characterization. Int J Pharm. 2013;454:573\u201384.","journal-title":"Int J Pharm"},{"key":"1795_CR26","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.ijbiomac.2016.07.020","volume":"92","author":"V Kumar","year":"2016","unstructured":"Kumar V, Kharb R, Chaudhary H. Optimization & design of isradipine loaded solid lipid nanobioparticles using rutin by Taguchi methodology. Int J Biol Macromol. 2016;92:338\u201346.","journal-title":"Int J Biol Macromol"},{"key":"1795_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2017\/8274927","volume":"2017","author":"S Rehman","year":"2017","unstructured":"Rehman S, Nabi B, Fazil M, Khan S, Bari NK, Singh R, et al. Role of P-glycoprotein inhibitors in the bioavailability enhancement of solid dispersion of darunavir. Biomed Res Int. 2017;2017:1\u201317. https:\/\/doi.org\/10.1155\/2017\/8274927.","journal-title":"Biomed Res Int"},{"issue":"3","key":"1795_CR28","doi-asserted-by":"publisher","first-page":"151","DOI":"10.5958\/2231-5675.2017.00024.2","volume":"7","author":"V Swetha","year":"2017","unstructured":"Swetha V, Prasad SVUM, Rani YA. Analytical method development and validation for simultaneous estimation of Cobicistat and Elvitegravir by using RP-HPLC in pure and pharmaceutical dosage form. Asian J Pharm Anal. 2017;7(3):151\u20138.","journal-title":"Asian J Pharm Anal"},{"issue":"2","key":"1795_CR29","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1039\/C7NR07736J","volume":"10","author":"N Shrestha","year":"2018","unstructured":"Shrestha N, Bouttefeux O, Vanvarenberg K, Lundquist P, Cunarro J, Tovar S, et al. The stimulation of GLP-1 secretion and delivery of GLP-1 agonists via nanostructured lipid carriers. Nanoscale. 2018;10(2):603\u201313.","journal-title":"Nanoscale."},{"key":"1795_CR30","doi-asserted-by":"publisher","unstructured":"Mudalige T, Qu H, Van Haute D, Ansar SM, Paredes A, Ingle T. Characterization of nanomaterials. Nanomater Food Appl. 2019:313\u201353. https:\/\/doi.org\/10.1016\/b978-0-12-814130-4.00011-7.","DOI":"10.1016\/b978-0-12-814130-4.00011-7"},{"issue":"10","key":"1795_CR31","doi-asserted-by":"publisher","first-page":"3382","DOI":"10.1016\/j.xphs.2019.06.003","volume":"108","author":"A Singh","year":"2019","unstructured":"Singh A, Neupane YR, Mangla B, Kohli K. Nanostructured lipid carriers for oral bioavailability enhancement of exemestane: formulation design, in vitro, ex vivo, and in vivo studies. J Pharm Sci. 2019;108(10):3382\u201395. https:\/\/doi.org\/10.1016\/j.xphs.2019.06.003.","journal-title":"J Pharm Sci"},{"issue":"2","key":"1795_CR32","doi-asserted-by":"publisher","first-page":"288","DOI":"10.3109\/03639045.2015.1052078","volume":"42","author":"S Verma","year":"2016","unstructured":"Verma S, Singh SK, Verma PR. Fabrication of lipidic nanocarriers of loratadine for facilitated intestinal permeation using multivariate design approach. Drug Dev Ind Pharm. 2016;42(2):288\u2013306. https:\/\/doi.org\/10.3109\/03639045.2015.1052078.","journal-title":"Drug Dev Ind Pharm"},{"issue":"1","key":"1795_CR33","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1080\/1061186X.2016.1191080","volume":"25","author":"M Rizwanullah","year":"2017","unstructured":"Rizwanullah M, Amin S, Ahmad J. Improved pharmacokinetics and antihyperlipidemic efficacy of rosuvastatin-loaded nanostructured lipid carriers. J Drug Target. 2017;25(1):58\u201374.","journal-title":"J Drug Target"},{"key":"1795_CR34","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.ejpb.2016.10.011","volume":"109","author":"S Khan","year":"2016","unstructured":"Khan S, Shaharyar M, Fazil M, Hassan MQ, Baboota S, Ali J. Tacrolimus-loaded nanostructured lipid carriers for oral delivery-in vivo bioavailability enhancement. Eur J Pharm Biopharm. 2016;109:149\u201357. https:\/\/doi.org\/10.1016\/j.ejpb.2016.10.011.","journal-title":"Eur J Pharm Biopharm"},{"key":"1795_CR35","unstructured":"Lyne G, Mouna L, Francois L, Pichette V. Medium chain length fatty acids and glycerides as nephroprotection agents. Australian Patent. AU2008318196. 2014."},{"key":"1795_CR36","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.ijpharm.2013.12.006","volume":"461","author":"LM Negi","year":"2014","unstructured":"Negi LM, Jaggi M, Talegaonkar S. Development of protocol for screening the formulation components and the assessment of common quality problems of nano-structured lipid carriers. Int J Pharm. 2014;461:403\u201310.","journal-title":"Int J Pharm"},{"key":"1795_CR37","doi-asserted-by":"publisher","unstructured":"Eh Suk VR, Latif MF, Teo YY, Misran M. Development of nanostructured lipid carrier (NLC) assisted with polysorbate nonionic surfactants as a carrier for L-ascorbic acid and Gold Tri.E 30. J Food Sci Technol. 2020. https:\/\/doi.org\/10.1007\/s13197-020-04357-x.","DOI":"10.1007\/s13197-020-04357-x"},{"key":"1795_CR38","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.ejps.2009.04.008","volume":"37","author":"RK Subedi","year":"2009","unstructured":"Subedi RK, Kang KW, Choi HK. Preparation and characterization of solid lipid nanoparticles loaded with doxorubicin. Eur J Pharm Sci. 2009;37:508\u201313.","journal-title":"Eur J Pharm Sci"},{"key":"1795_CR39","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s40199-019-00304-0","volume":"27","author":"SSVS Palagati","year":"2019","unstructured":"Palagati SSVS, Kesavan BR. Application of computational tools for the designing of oleuropein loaded nanostructured lipid carrier for brain targeting through nasal route. DARU. 2019;27:695\u2013708. https:\/\/doi.org\/10.1007\/s40199-019-00304-0.","journal-title":"DARU."},{"issue":"3","key":"1795_CR40","doi-asserted-by":"publisher","first-page":"617","DOI":"10.3109\/21691401.2016.1167699","volume":"45","author":"SM Moghddam","year":"2017","unstructured":"Moghddam SM, Ahad A, Aqil M, Imam SS, Sultana Y. Optimization of nanostructured lipid carriers for topical delivery of nimesulide using Box-Behnken design approach. Artif Cells Nanomed Biotechnol. 2017;45(3):617\u201324.","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"1795_CR41","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.ejpb.2010.05.003","volume":"76","author":"Z Rahman","year":"2010","unstructured":"Rahman Z, Zidan AS, Khan MA. Non-destructive methods of characterization of risperidone solid lipid nanoparticles. Eur J Pharm Biopharm. 2010;76:127\u201337.","journal-title":"Eur J Pharm Biopharm"},{"key":"1795_CR42","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.foodchem.2015.03.069","volume":"186","author":"Z Guo","year":"2015","unstructured":"Guo Z, Zeng S, Lu X, Zhou M, Zheng M, Zheng B. Structural and physicochemical properties of lotus seed starch treated with ultra-high pressure. Food Chem. 2015;186:223\u201330.","journal-title":"Food Chem"},{"issue":"3","key":"1795_CR43","doi-asserted-by":"publisher","first-page":"342","DOI":"10.3109\/10837450.2013.784336","volume":"19","author":"A Siddiqui","year":"2014","unstructured":"Siddiqui A, Alayoubi A, El-Malah Y, Nazzal S. Modeling the effect of sonication parameters on size and dispersion temperature of solid lipid nanoparticles (SLNs) by response surface methodology (RSM). Pharm Dev Technol. 2014;19(3):342\u20136.","journal-title":"Pharm Dev Technol"},{"issue":"6","key":"1795_CR44","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1208\/s12249-014-0175-y","volume":"15","author":"TH Tran","year":"2014","unstructured":"Tran TH, Ramasamy T, Truong DH, Choi HG, Yong CS, Kim JO. Preparation and characterization of fenofibrate-loaded nanostructured lipid carriers for oral bioavailability enhancement. AAPS PharmSciTech. 2014;15(6):1509\u201315.","journal-title":"AAPS PharmSciTech"},{"issue":"84","key":"1795_CR45","doi-asserted-by":"publisher","first-page":"68743","DOI":"10.1039\/C5RA10642G","volume":"5","author":"S Kumar","year":"2015","unstructured":"Kumar S, Randhawa JK. Solid lipid nanoparticles of stearic acid for the drug delivery of paliperidone. RSC Adv. 2015;5(84):68743\u201350.","journal-title":"RSC Adv"},{"issue":"6","key":"1795_CR46","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1208\/s12249-016-0657-1","volume":"18","author":"HM Helal","year":"2017","unstructured":"Helal HM, Mortada SM, Sallam MA. Paliperidone-loaded nanolipomer system for sustained delivery and enhanced intestinal permeation: superiority to polymeric and solid lipid nanoparticles. AAPS PharmSciTech. 2017;18(6):1946\u201359.","journal-title":"AAPS PharmSciTech"},{"key":"1795_CR47","doi-asserted-by":"publisher","first-page":"5449","DOI":"10.2147\/IJN.S73010","volume":"9","author":"RN Shamma","year":"2014","unstructured":"Shamma RN, Aburahma MH. Follicular delivery of spironolactone via nanostructured lipid carriers for management of alopecia. Int J Nanomedicine. 2014;9:5449\u201360.","journal-title":"Int J Nanomedicine"},{"key":"1795_CR48","doi-asserted-by":"publisher","first-page":"119033","DOI":"10.1016\/j.ijpharm.2020.119033","volume":"577","author":"N Khan","year":"2020","unstructured":"Khan N, Shah FA, Rana I, Ansari MM, Ud Din F, Rizvi SZH, et al. Nanostructured lipid carriers-mediated brain delivery of carbamazepine for improved in vivo anticonvulsant and anxiolytic activity. Int J Pharm. 2020;577:119033. https:\/\/doi.org\/10.1016\/j.ijpharm.2020.119033.","journal-title":"Int J Pharm"},{"key":"1795_CR49","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.ejpb.2016.07.026","volume":"108","author":"VM Ghate","year":"2016","unstructured":"Ghate VM, Lewis SA, Prabhu P, Dubey A, Patel N. Nanostructured lipid carriers for the topical delivery of tretinoin. Eur J Pharm Biopharm. 2016;108:253\u201361.","journal-title":"Eur J Pharm Biopharm"},{"issue":"3","key":"1795_CR50","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0033253","volume":"7","author":"S Forster","year":"2012","unstructured":"Forster S, Thumser AE, Hood SR, Plant N. Characterization of Rhodamine-123 as a tracer dye for use in in vitro drug transport assays. PLoS One. 2012;7(3):e33253. https:\/\/doi.org\/10.1371\/journal.pone.0033253.","journal-title":"PLoS One"},{"key":"1795_CR51","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nrd2197","volume":"6","author":"C Porter","year":"2007","unstructured":"Porter C, Trevaskis N, Charman W. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Dics. 2007;6:231\u201348.","journal-title":"Nat Rev Drug Dics"},{"issue":"1\u20133","key":"1795_CR52","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/s0005-2728(03)00110-5","volume":"1606","author":"A Baracca","year":"2003","unstructured":"Baracca A, Sgarbi G, Solaini G, Lenaz G. Rhodamine 123 as a probe of mitochondrial membrane potential: evaluation of proton flux through F(0) during ATP synthesis. Biochim Biophys Acta. 2003;1606(1\u20133):137\u201346. https:\/\/doi.org\/10.1016\/s0005-2728(03)00110-5.","journal-title":"Biochim Biophys Acta"}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-020-01795-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12249-020-01795-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-020-01795-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,23]],"date-time":"2021-09-23T23:05:52Z","timestamp":1632438352000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12249-020-01795-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,24]]},"references-count":52,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["1795"],"URL":"https:\/\/doi.org\/10.1208\/s12249-020-01795-w","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,24]]},"assertion":[{"value":"17 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted according to the Institutional Animal Ethics Committee (173\/CPCSEA, 28 January 2000; Approval no. 1458), Jamia Hamdard and all guidelines were adhered to.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"2019 AAPS PharmSci 360, USA, and IPA Convention 2019 PharmaRIA.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Prior Presentations"}}],"article-number":"261"}}